Providence Cancer Therapy Radiology Oncology Cente is categorized under Oncologists in Anchorage, AK and active since 2010.
Providence Cancer Therapy Radiology Oncology Cente was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Oncologists business, which does work in the B2C market, and is classified as a Oncologists, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact at the company’s single location by writing to 3851 Piper St, Anchorage, Alaska AK 99508 or by phoning (907) 212-3186. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Providence Cancer Therapy Radiology Oncology Cente |
| Address: | 3851 Piper St, Anchorage, Alaska 99508 |
| Phone Number: | (907) 212-3186 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Oncologists |
| SIC Code: | 8011 |
| NAICS Code: | 621111 |
| Share This Business: |
Providence Cancer Therapy Radiology Oncology Cente was started in 2010 to provide professional Oncologists under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact for inquiries that concern Providence Cancer Therapy Radiology Oncology Cente by calling the company number (907) 212-3186, as your correspondence is most welcome. Additionally, the physical location of the single location of Providence Cancer Therapy Radiology Oncology Cente can be found at the coordinates 61.186709,-149.827171 as well as the street address 3851 Piper St in Anchorage, Alaska 99508.
For its online presence, you may visit Providence Cancer Therapy Radiology Oncology Cente’s website at and engage with its social media outlets through on Twitter and on Facebook.